Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-adapted R-MegaCHOP with early R-IFE and autologous stem cell transplant in poor-prognosis diffuse large B-cell lymphoma
2006-005254-68Phase 4Active
- Sponsor
- GEL/TAMO (Cooperative Spanish Group of Lymphoma/Autologous bone marrow transplant).
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and 2 more in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (2 arms), sponsored by GEL/TAMO (Cooperative Spanish Group of Lymphoma/Autologous bone marrow transplant). Primary endpoint: Event-free survival at 3 years. Started Jan 2007; status: active.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2006-005254-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005254-68.